Q1 Earnings Estimate for CLRB Issued By Roth Capital

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Investment analysts at Roth Capital issued their Q1 2025 earnings per share estimates for shares of Cellectar Biosciences in a research note issued on Monday, November 18th. Roth Capital analyst J. Aschoff expects that the biopharmaceutical company will earn ($0.26) per share for the quarter. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.57) per share.

Cellectar Biosciences (NASDAQ:CLRB) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter.

Several other equities research analysts have also recently weighed in on CLRB. StockNews.com upgraded Cellectar Biosciences to a “sell” rating in a research note on Thursday, September 26th. Oppenheimer dropped their price objective on Cellectar Biosciences from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Tuesday.

Cellectar Biosciences Trading Down 9.0 %

Shares of Cellectar Biosciences stock opened at $1.61 on Wednesday. The company has a market cap of $65.32 million, a PE ratio of -0.63 and a beta of 1.00. The company has a 50 day moving average of $2.07 and a 200-day moving average of $2.42. Cellectar Biosciences has a 1-year low of $1.57 and a 1-year high of $4.45.

Hedge Funds Weigh In On Cellectar Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLRB. Geode Capital Management LLC grew its stake in shares of Cellectar Biosciences by 3.3% during the third quarter. Geode Capital Management LLC now owns 352,452 shares of the biopharmaceutical company’s stock worth $754,000 after buying an additional 11,266 shares during the last quarter. Oppenheimer & Co. Inc. bought a new stake in Cellectar Biosciences during the 3rd quarter worth $27,000. Sequoia Financial Advisors LLC bought a new stake in Cellectar Biosciences during the 3rd quarter worth $51,000. XTX Topco Ltd increased its holdings in Cellectar Biosciences by 432.4% in the 2nd quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 51,413 shares in the last quarter. Finally, AIGH Capital Management LLC raised its position in Cellectar Biosciences by 8.2% in the second quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock valued at $7,590,000 after purchasing an additional 231,270 shares during the last quarter. Institutional investors own 16.41% of the company’s stock.

About Cellectar Biosciences

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.